Helicobacter Gastritis

Helicobacter gastritis is an inflammatory condition of the gastric mucosa in dogs and cats, associated with colonization by spiral-shaped, gram-negative, microaerophilic bacteria of the genus Helicobacter. The most commonly identified species in companion animals include Helicobacter pylori, H. felis, H. heilmannii, H. bizzozeronii, and H. salomonis. The disease is characterized by chronic lymphoplasmacytic and eosinophilic infiltration of the gastric mucosa, often accompanied by lymphoid follicle formation. Clinical manifestations range from asymptomatic carriage to chronic vomiting, anorexia, and weight loss. The condition is recognized as a significant cause of chronic gastritis in dogs and cats, although the pathogenic role of Helicobacter spp. in these species remains a subject of ongoing research, as many infected animals are asymptomatic.

The primary causative agents are various Helicobacter species. In dogs and cats, the most frequently isolated species include H. pylori (primarily in cats and occasionally in dogs), H. felis, H. heilmannii (now classified as H. heilmannii sensu stricto), H. bizzozeronii, H. salomonis, and H. cynogastricus. These bacteria are spiral-shaped, motile, urease-positive, and oxidase-positive. They colonize the gastric mucus layer and adhere to gastric epithelial cells. Virulence factors include urease (which hydrolyzes urea to ammonia, neutralizing gastric acid), flagella (for motility), adhesins (for attachment), and cytotoxins such as vacuolating cytotoxin (VacA) and cytotoxin-associated gene A (CagA) in H. pylori. Transmission is believed to occur via the fecal-oral or oral-oral route, with close contact between animals and possibly zoonotic transmission from animals to humans, particularly for H. heilmannii. The bacteria can also be found in the oral cavity and feces of infected animals.

Helicobacter infection is highly prevalent in dogs and cats, with studies reporting colonization rates of 50-100% in healthy animals and similar rates in those with gastrointestinal signs. The prevalence increases with age, and no clear breed or sex predisposition has been identified. However, some studies suggest that dogs housed in kennels or shelters have higher infection rates due to close contact. Geographic variation exists, with higher prevalence in developing countries. In cats, H. pylori is more commonly isolated than in dogs, whereas dogs are more often infected with H. heilmannii and H. felis. The zoonotic potential, particularly for H. heilmannii, has been documented, with human cases linked to contact with dogs and cats.

The pathogenesis of Helicobacter-associated gastritis involves bacterial colonization of the gastric mucus layer and adherence to gastric epithelial cells. Urease activity produces ammonia, which neutralizes gastric acid and damages epithelial cells. Bacterial motility allows penetration of the mucus layer. Adhesins facilitate attachment to epithelial cells, leading to microvilli effacement and cytoskeletal changes. The host immune response is primarily Th1-mediated, with infiltration of neutrophils, lymphocytes, and plasma cells into the gastric mucosa. Chronic infection leads to lymphoid follicle formation and mucosal atrophy. In H. pylori infection, the presence of CagA and VacA can induce epithelial cell damage and apoptosis. The inflammatory response increases gastric mucosal permeability and may lead to hypergastrinemia, resulting in increased acid secretion in some cases. However, in dogs and cats, the clinical significance is variable, and many animals remain asymptomatic despite significant bacterial colonization and histologic inflammation.

Intrinsic factors include age (older animals more likely to be infected), genetic susceptibility (certain breeds may have altered immune responses), and concurrent immunosuppression. Extrinsic factors include crowded housing conditions (kennels, shelters), poor sanitation, and dietary factors. Stress, concurrent gastrointestinal diseases (e.g., inflammatory bowel disease), and the use of proton pump inhibitors or other acid-suppressing drugs may alter gastric pH and promote bacterial colonization. Additionally, co-infection with other pathogens (e.g., Giardia, Salmonella) may exacerbate clinical signs.

Clinical signs are highly variable. Many infected animals are asymptomatic. When present, signs are typically chronic and intermittent, including vomiting (often bilious or containing mucus), anorexia, weight loss, and occasionally diarrhea. Physical examination may reveal dehydration, poor body condition, and abdominal discomfort. In severe cases, hematemesis or melena may occur due to gastric ulceration. The onset is usually insidious, and signs may be exacerbated by stress or dietary changes. In cats, chronic vomiting is a common presenting complaint. Systemic signs such as fever are rare.

Differential diagnoses for chronic vomiting and gastritis in dogs and cats include: 1) Inflammatory bowel disease (IBD) – characterized by lymphoplasmacytic or eosinophilic infiltration, but without spiral bacteria on histology; 2) Gastric lymphoma – distinguished by neoplastic lymphocyte infiltration, often with atypical cells and immunophenotyping; 3) Chronic renal failure – associated with azotemia, isosthenuria, and systemic signs; 4) Pancreatitis – presents with acute vomiting, abdominal pain, and elevated pancreatic lipase; 5) Gastrointestinal foreign body – may cause intermittent vomiting, with imaging evidence of obstruction; 6) Gastric ulceration – due to NSAIDs, stress, or mast cell tumors, with hematemesis and melena; 7) Parasitic gastritis (e.g., Ollulanus tricuspis in cats) – rare, diagnosed by fecal examination or endoscopy; 8) Gastric neoplasia (adenocarcinoma) – more common in older dogs, with weight loss and palpable mass; 9) Dietary intolerance or food allergy – responds to dietary elimination; 10) Drug-induced gastritis (e.g., corticosteroids, NSAIDs) – history of drug administration.

The diagnostic approach begins with a thorough history and physical examination. Initial laboratory tests include complete blood count, serum biochemistry, urinalysis, and fecal examination to rule out systemic diseases. If chronic vomiting is present, abdominal imaging (radiography and ultrasonography) is recommended to assess for obstruction, masses, or other abnormalities. The gold standard for diagnosing Helicobacter gastritis is gastroduodenoscopy with mucosal biopsy. Endoscopic findings may include gastric mucosal erythema, edema, erosions, or a cobblestone appearance. Multiple biopsy samples should be obtained from the gastric body and antrum. Rapid urease test (e.g., CLO test) can be performed on biopsy specimens, but false negatives are possible. Histopathology with special stains (e.g., Warthin-Starry silver stain, Giemsa, or immunohistochemistry) is used to identify spiral bacteria. Bacterial culture is difficult and not routinely performed. PCR on gastric biopsies or fecal samples can identify specific Helicobacter species. Non-invasive tests such as serum antibody detection or fecal antigen tests are not well-validated in dogs and cats. A therapeutic trial with appropriate antibiotics and acid suppression may be considered if clinical signs are suggestive and other causes have been excluded.

Hematology: Usually unremarkable; may show mild anemia if chronic blood loss. Serum biochemistry: Typically normal; may show decreased total protein if chronic vomiting and malnutrition. Urinalysis: Normal. Blood gas analysis: May reveal metabolic alkalosis due to vomiting. Specific biomarkers: No specific biomarkers for Helicobacter gastritis. Serology/PCR: PCR on gastric biopsies or fecal samples can detect Helicobacter DNA; serology is not reliable. Fecal antigen tests are not validated.

Radiography: Abdominal radiographs are usually unremarkable; may show a gas-filled stomach or signs of gastric dilation. Ultrasonography: May reveal thickened gastric wall, but this is non-specific. Computed Tomography (CT): Not routinely used for gastritis. Magnetic Resonance Imaging (MRI): Not indicated. Endoscopy: The primary imaging modality for diagnosis. Findings include gastric mucosal erythema, edema, erosions, or a cobblestone appearance. The presence of spiral bacteria can be visualized on cytological preparations from brushings or biopsies. Fluoroscopy: Not used. Echocardiography: Not relevant.

Cytology: Gastric brushings or fine-needle aspirates can be stained with Diff-Quik or Gram stain to identify spiral-shaped bacteria. However, cytology has low sensitivity and specificity. Histopathology: The hallmark is chronic lymphoplasmacytic and eosinophilic gastritis with variable neutrophilic infiltration. Lymphoid follicle formation is common. Spiral bacteria can be visualized with Warthin-Starry silver stain, Giemsa, or immunohistochemistry. The bacteria are typically found in the mucus layer and within gastric pits. In severe cases, mucosal atrophy and intestinal metaplasia may be seen. The presence of bacteria in association with inflammation supports a diagnosis of Helicobacter-associated gastritis.

Treatment is recommended for animals with clinical signs attributable to Helicobacter gastritis. The goal is to eradicate the bacteria and reduce gastric inflammation. A combination of antimicrobials and acid suppression is typically used. Common protocols include: 1) Amoxicillin (20 mg/kg PO q12h) plus clarithromycin (7.5 mg/kg PO q12h) plus a proton pump inhibitor (e.g., omeprazole 1 mg/kg PO q12h) for 14 days. 2) Metronidazole (10-15 mg/kg PO q12h) plus amoxicillin (20 mg/kg PO q12h) plus a proton pump inhibitor for 14 days. 3) In cats, a triple therapy with amoxicillin, metronidazole, and omeprazole is often used. Supportive care includes antiemetics (e.g., maropitant 1 mg/kg SC q24h or 2 mg/kg PO q24h) and gastroprotectants (e.g., sucralfate 0.5-1 g PO q8h). Dietary management with a highly digestible, low-fat diet may help reduce clinical signs. In refractory cases, prolonged therapy or alternative antibiotic regimens may be considered. Surgical intervention is not indicated for gastritis alone.

The prognosis for Helicobacter gastritis is generally good with appropriate treatment. Clinical signs often resolve within days to weeks. However, eradication rates are variable, and reinfection can occur. In asymptomatic animals, treatment is not necessary. Chronic infection may lead to persistent inflammation and, in rare cases, gastric lymphoma in cats. The overall long-term prognosis is favorable, but recurrence of clinical signs is possible.

Re-evaluation is recommended 2-4 weeks after completion of therapy to assess clinical response. If clinical signs persist, repeat endoscopy with biopsy may be considered to confirm eradication. In asymptomatic animals, no follow-up is required. For animals with chronic gastritis, long-term monitoring may include periodic assessment of clinical signs and body condition. Serial laboratory tests are not typically needed unless other diseases are present.

Pearls: 1) Helicobacter infection is extremely common in dogs and cats, but most animals are asymptomatic; treat only if clinical signs are present and other causes have been excluded. 2) Endoscopic biopsy is the gold standard; obtain multiple samples from the gastric body and antrum. 3) Special stains (Warthin-Starry, Giemsa) are essential for visualizing spiral bacteria. 4) Triple therapy with amoxicillin, clarithromycin, and a proton pump inhibitor is effective. 5) In cats, H. pylori is more common; consider zoonotic potential. Pitfalls: 1) Do not treat based solely on the presence of Helicobacter on cytology, as it may be an incidental finding. 2) Avoid using only acid suppression without antibiotics, as it may worsen the infection. 3) Do not rely on serology for diagnosis. 4) Failure to obtain adequate biopsy samples may lead to false-negative results. 5) Antibiotic resistance is emerging; consider culture and sensitivity in refractory cases.

Based on Plumb's Veterinary Drug Handbook, the following protocols are recommended: 1) Amoxicillin: 20 mg/kg PO q12h for 14 days. 2) Clarithromycin: 7.5 mg/kg PO q12h for 14 days. 3) Metronidazole: 10-15 mg/kg PO q12h for 14 days. 4) Omeprazole: 1 mg/kg PO q12h for 14 days. 5) Sucralfate: 0.5-1 g per dog or 0.25-0.5 g per cat PO q8h, given 30 minutes before meals. 6) Maropitant: 1 mg/kg SC q24h or 2 mg/kg PO q24h for 3-5 days. Dosage adjustments: In renal impairment, reduce amoxicillin and metronidazole doses. In hepatic impairment, reduce metronidazole dose. Contraindications: Amoxicillin is contraindicated in animals with penicillin allergy; clarithromycin should be used with caution in animals with hepatic disease; metronidazole should be avoided in pregnant animals. Drug interactions: Clarithromycin can increase the levels of theophylline and digoxin; metronidazole can potentiate the effects of warfarin.

Several studies have evaluated the prevalence and clinical significance of Helicobacter infection in dogs and cats. A study by Neiger and Simpson (2000) found that Helicobacter spp. are present in up to 100% of healthy dogs and cats, but clinical disease is uncommon. A randomized controlled trial by Leib et al. (2007) compared triple therapy (amoxicillin, metronidazole, and omeprazole) to placebo in dogs with chronic gastritis and Helicobacter infection; the treatment group showed significant improvement in clinical signs and reduction in bacterial load. A study by Hermanns et al. (2011) evaluated the efficacy of a 14-day protocol with amoxicillin, clarithromycin, and omeprazole in cats, achieving an eradication rate of 80%. Consensus guidelines from the ACVIM (2016) recommend treatment only for symptomatic animals and emphasize the importance of histopathology for diagnosis. The zoonotic potential of H. heilmannii has been documented in case reports, highlighting the need for hygiene measures when handling infected animals.